Cardiogenic thromboembolism is the mechanism responsible for upwards of 100 000 cases of ischaemic stroke annually among North Americans. Although fewer than the number caused by cerebrovascular diseases, these produce considerable disability and a cost of nearly a billion dollars annually for acute and convalescent care for stroke victims. Over half the strokes of cardiac origin occur in patients with atrial fibrillation, a relatively common cardiac rhythm disturbance with a prevalence of 21.5 per 1000 men and 17.1 per 1000 women in the Framingham Heart Study population. This and other epidemiologic studies have estimated the risk of stroke and systemic embolism associated with atrial fibrillation as five to six events per 100 patient-years, roughly five times the rate among comparable patients without this cardiac rhythm disturbance, and accumulating to a 35% lifetime risk of stroke for patients with atrial fibrillation. The risk appears related to age, such that among stroke victims over 85 years of age a history of atrial fibrillation can be found in nearly half. These strokes are typically devastating clinical events which leave survivors with lasting disability, but there is an additional incidence of subclinical 'silent' strokes which may take an uncounted toll on cognitive function, perhaps contributing to the problem of multi-infarct dementia among the elderly Stratification of thromboembolic risk High-risk situations: rheumatic valvular heart disease and recent thromboembolism Some patients with atrial fibrillationthose, for example, with rheumatic valvular heart disease or prosthetic heart valveshave long been recognized as in particular danger of stroke and systemic embolism. These patients carry at least an 8-10% per year risk of ischaemic thromboembolic events, enough to justify in the minds of most clinicians the haemorrhagic risks associated with maintenance anticoagulant therapy with an agent such as warfarin, even in the absence of randomized trials. 5 Among those with nonvalvular atrial fibrillation, the risk appears greatest when stroke or systemic embolism has occurred within the previous two years -in such cases the risk of recurrent stroke is even greater than 10% per year. 6, 7 Several reports suggest that patients with atrial fibrillation in the setting of thyrotoxicosis, often associated with decompensated congestive heart failure, are also at particularly high risk (averaging 14% over varying periods of observation), ~g though the exact mechanism underlying this embolic potential is not clear.9-11
The notion of increased thromboembolic risk in thyrotoxic atrial fibrillation has been challenged on the basis of comparison between these patients and those with thyrotoxicosis in sinus rhythm; a logistic regression analysis found only age an independent predictor of cerebral ischaemic events In this study, however, 13 % of patients with atrial fibrillation had ischaemic cerebrovascular events, compared with 3% of those with normal sinus rhythm, and when transient ischaemic attacks are discounted the increased risk of stroke in patients with atrial fibrillation did reach statistical significance (p = 0.03). Like atrial fibrillation in patients with associated rheumatic valvular heart disease or cardiac valvular prostheses, those with recent stroke or embolism and those with thyrotoxicosis should probably be treated with anticoagulant medication unless a contraindication to such therapy stands in the way, at least until a euthyroid state has been restored and congestive heart failure has been corrected.
Lone atrial fibrillation
On the other end of the spectrum of risk are patients younger than 60 years of age with 'lone' atrial fibrillation in the absence of clinical history, symptoms, signs or echocardiographic evidence of associated cardiopulmonary disease. These patients represent between 2.7% and 11.4% of cases of atrial fibrillation. 13 Kopecki reported the findings of a cohort study involving 99 such patients extending over nearly 15 years in Olmstead County, Minnesota, in which the incidence of stroke was 0.4% per year and the mortality rate was 0.1% per year, not significantly greater than rates in patients with normal sinus rhythm.14 Since lone atrial fibrillation is associated with such a low risk of stroke, it appears that the rhythm disturbance itself is not the cause of stroke but rather represents a marker of associated cardiovascular pathology which is the real culprit. Older age, hypertension and congestive heart failure are among the factors which substantially increase the stroke risk in the presence of atrial fibrillation Nonvalvular atrial fibrillation in patients with cardiac disease Between these extremes are a large number of patients with nonvalvular atrial fibrillation at intermediate risk of thromboembolism, which appears, based both upon older epidemiologic data and more recently available results of randomized trials, to average about 5% per year.
The range of risk is relatively wide (at least 3 and perhaps more than 8% per year), reflecting the demographic diversity of this patient population and partially accounting for the controversy about anticoagulant therapy, particularly when this is contemplated for an extended period of time. Clinicians have long suspected that within this broad range of patients with atrial fibrillation subgroups at relatively greater or lesser risk might be defined on the basis of clinical or echocardiographic features. Duration since the onset of atrial fibrillation, for example, has been suspected to relate to embolic risk.15 Differences in rates of thromboembolic events have also been cited on the basis of the constant or paroxysmal character of atrial fibrillation,16 and the presence or absence of hypertension, congestive heart failure, or mitral regurgitation.3 Enlargement of the left atrium, seemingly a correlate of stasis within the atrial appendage, has eluded validation as a particular marker of stroke risk,17-19 but recent studies have supported the view that associated left ventricular dysfunction may contribute an important element of risk. 20
Mechanisms of stroke
The aetiologies of ischaemic stroke in patients with nonvalvular atrial fibrillation are diverse, ranging from emboli derived from distant stasisrelated thrombi in the left atrium or left ventricle, to thrombotic complications of associated cerebrovascular disease.3,20,21 Abnormal endocardial tissue surfaces, including myxomatous or fibrotic mitral valve leaflets, mitral annular dilatation or calcification, damaged chordae tendinae or other lesions may stimulate platelet aggregation as well as the coagulation system. Atherosclerotic lesions in the aorta, extracranial or intracranial arteries may reduce cerebral perfusion by direct obstruction or as a result of thrombus formation provoked by exposure of lipid material and subintimal vascular collagen. 22 The prevalence of atherosclerotic disease of the carotid arteries is twice as great in patients with atrial fibrillation as in age-matched controls, but only one in four patients with atrial fibrillation and stroke have significant carotid disease apparent on ultrasound examination. 23, 24 Clinical estimates of the incidence of cardiogenic embolism as the aetiology of stroke in patients with atrial fibrillation are difficult to verify and vary widely, but are generally in excess of 50%.3 3 Systemic emboli in patients with atrial fibrillation are suspected to originate as thrombi formed within the left atrial cavity or appendage.25 To the extent that stasis-related thrombi are responsible for ischaemic stroke in patients with atrial fibrillation, administration of anticoagulant medication such as warfarin represents a logical preventive approach. The presence of endothelial lesions within the heart or blood vessels which might be a nidus for thrombus formation raises the likelihood of a response to platelet inhibitors such as aspirin. 22 The differential responses to warfarin and aspirin in recent clinical trials of antithrombotic therapy in patients with nonvalvular atrial fibrillation may reflect, in part, the relative predominance of these aetiologic properties.
Clinical trials of antithrombotic therapy
Over the past several years, no fewer than six prospective trials aimed at the primary prevention of stroke and systemic embolism in patients with atrial fibrillation have been undertaken, and results from four have been reported.26-29 While these share certain features, there are sufficient differences in the demographics of the populations investigated, specific trial designs and results to leave some issues still in dispute. Salient The Copenhagen Atrial Fibrillation-Aspirin-Anticoagulation (AFASAK) study26 involved 1007 patients with constant atrial fibrillation randomly assigned to therapy with warfarin (prothrombin time prolonged to an International Normalized Ratio (INR) of 2.8-4.2), aspirin (75mg daily), or placebo, followed for a mean of 11 months with primary endpoint events ischaemic stroke, transient cerebral ischaemia and systemic embolism. Although 38% of patients assigned to anticoagulant therapy were withdrawn, warfarin seemed protective while aspirin did not. The mean patient age was 74 years, and the prevalence of congestive heart failure (51%) was greater than in the other trials.27-29 The proportion of women was more evenly balanced with men than in the other trials, although the Framingham Study found no difference in the incidence of atrial fibrillation on the basis of gender.
The Stroke Prevention in Atrial Fibrillation (SPAF) Study27 randomized 1244 patients with either intermittent (34%) or constant atrial fibrillation who were candidates for anticoagulation (Group I) to receive warfarin (INR 1.7-4.5), aspirin (325mg per day,) or placebo, and those ineligible for warfarin (Group II) to receive either aspirin or placebo. Only the aspirin and placebo arms were blinded. The mean age in this study was 67 years, and only 10.9% of patients assigned to warfarin were withdrawn. The primary events were ischaemic stroke and systemic embolism.
Patients were followed for a mean of 1.13 years when placebo administration was terminated because the event rate with active therapy (1.6% per year) was less than with placebo (8.3% per year) in Group I (risk reduction 81%). Among all 517 patients given aspirin, the rate of primary events was 3.2% per year, compared with 6.3% per year in those given placebo (Groups I and II combined; risk reduction 49 % ; p < 0.02). The benefit of aspirin seemed to evaporate in patients over the age of 75 years.
In the Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)28 420 patients (35% with paroxysmal rather than constant atrial fibrillation) were randomly assigned to warfarin (INR 1.5-2.7) or control groups. Aspirin was permitted in the control group, and reportedly taken by 46%. Follow-up extended over a mean of 2.2 years, and the primary endpoint event was ischaemic stroke. The incidence of stroke was very low in the group given warfarin (0.41 % per year) compared with the control group (3.0% per year; risk reduction 86%). The mortality rate was also lower in patients assigned to warfarin (2.3% per year) than to placebo (6.0% per year), particularly for death attributed to noncardiac causes. The mean age was 68 and only 10% of warfarin patients stopped therapy. Twenty-six per cent of patients had a history of congestive heart failure and 13% had previously sustained myocardial infarction, prevalences similar to those in the SPAF study. Mitral annular calcification (present in 30% of patients) and age were significantly related to stroke risk.
The results of the Canadian Atrial Fibrillation Anticoagulation (CAFA) Study have been reported only in preliminary form28; the trial was terminated before statistically meaningful endpoints were reached because of convincing results in other trials favouring antithrombotic therapy. Of all the published studies, however, this was the only one to incorporate a doubleblind design for administration of warfarin, and as such is of particular value as it avoids potential bias in event detection.
In none of these studies was the incidence of major haemorrhagic complications significantly increased with anticoagulant therapy, even though the average patient age was nearly 70 years (Table 1) . Taken together, these trials confirm observations in epidemiologic studies that the risk of ischaemic stroke in patients with nonvalvular atrial fibrillation is about 5 % per year, approximately 5-7 times that of the general population of comparable age and gender. Each study provides support for the view that anticoagulation with warfarin is effective in comparatively low intensity (INR 1.5-4.5) for reducing the risk of stroke in patients with nonvalvular atrial fibrillation by about 3% per year. This benefit offsets the increased risk of bleeding sufficiently severely to require hospitalization, transfusion or surgery (about 1-2% per year). Aspirin is also effective in reducing the incidence of ischaemic stroke in patients with atrial fibrillation, but the results of the two studies which included aspirin arms differed on the basis of aspirin dose and patient population. Secondary analysis of data from the SPAF study27 suggested reduced aspirin efficacy in older patients, which Table 1a Randomized trials of antithrombotic therapy in nonvalvular atrial fibrillation: design Table 1b Randomized trials of antithrombotic therapy in nonvalvular atrial fibrillation: patient features Table 1c Randomized trials of antithrombotic therapy in nonvalvular atrial fibrillation: outcome *Not placebo-controlled; value refers to control group, nearly half of which used aspirin for unspecified periods. might account, in part, for the minimal beneficial effect of aspirin in the AFASAK study.26 The lower incidence of stroke in the control group of the BAATAF study28 than in the SPAF and AFASAK studies may be due to the use of aspirin in nearly half the patients. As ischaemic stroke in patients with atrial fibrillation may involve any of a number of mechanisms, the disparate antithrombotic actions of aspirin (platelet inhibitor) and warfarin (anticoagulant) may prevent strokes of entirely different aetiologies. Indeed, the relative efficacy of warfarin and aspirin for prevention of disabling ischaemic cerebral events in patients with atrial fibrillation remains an unsettled issue and a priority for continued research. At this point, however, it seems reasonable to conclude that most patients with nonrheumatic cardiac disease associated with atrial fibrillation who can safely tolerate these antithrombotic medications should be given either aspirin or warfarin to prevent stroke and systemic embolism.
Abolition of atrial fibrillation

Anticoagulation at the time of cardioversion
The notion that risk of stroke should be greater around the time of chemical or electrical attempts to restore sinus rhythm in patients with atrial fibrillation is fraught with conjecture, particularly since spontaneous termination of episodes of atrial fibrillation among patients in whom fibrillation is paroxysmal is not associated with increased risks Nevertheless, several reports cite an unexpectedly high incidence of stroke within the first several days following successful electrical reversion to sinus rhythm by direct-current countershock, and suggest that the risk may be lowered by anticoagulant therapy ( Table 2) . 30 It is difficult to interpret these reports, however, because of the relatively high incidence of rheumatic heart disease subtending atrial fibrillation in many of the cases studied. In the largest study, 437 patients with a variety of atrial arrhythmias, 58% of whom had underlying rheumatic heart disease, underwent electrical cardioversion procedures with or without anticoagulant medication depending upon the practice of referring physicians. Those receiving anticoagulants had presumed embolic events at a rate of 0.8 incidents per 100 successful conversions, compared with 5.3% in those not anticoagulated (p = 0.016), despite a greater prevalence of rheumatic heart disease, congestive heart failure, prior embolism and cardiac enlargement among those receiving anticoagulants.31,32 Half of the thromboembolic events occurred in patients with nonrheumatic cardiac disorders. This study is mentioned not so much for its implications regarding therapy, which involved long-term rather than short-term anticoagulation, but because it illustrates the limitations imposed by nonrandomized design and other issues.33
Undoubtedly, a heightened awareness of danger may contribute to event detection under these circumstances, or patients at greater intrinsic risk of thromboembolism (such as those with left ventricular dysfunction) may more frequently be candidates for cardioversion. Just as it might be reasonably assumed that there should be no difference in rates of thromboembolism associated with spontaneous, chemical or electrical means of cardioversion, the risk of stroke at the time of cardioversion is most likely linked with the intrinsic cardiovascular factors which contribute to risk on a chronic basis. More aggressive use of anticoagulant medication may be justified for a period of three to four weeks prior to and another three to four weeks after cardioversion because of the reduced cumulative danger of haemorrhage when the intensity of anticoagulation is closely controlled over a relatively short period of time. The need for therapy over this interval is based upon the latency of the onset of cerebral ischaemic symptoms in some patients, which has been attributed to delayed activation of left atrial contractile function which retards the embolic propulsion of thrombus across the mitral orifice and into the circulation.34-36
Maintenance of sinus rhythm with antiarrhythmic medication Treatment which successfully maintains sinus rhythm in place of atrial fibrillation might suspend the need for antithrombotic therapy, with its attendant haemorrhagic complications, for prevention of systemic thromboembolism and ischaemic stroke. A variety of antiarrhythmic medications have been employed for this purpose. A meta-analysis of six randomized, placebo-controlled, double-blind trials incorpo- Table 2 Embolic risk during cardioversion for atrial fibrillation: summary of published reports *Calculated per successful cardioversion attempts; HCM = hypertrophic cardiomyopathy; RHD = rheumatic heart disease; A/C = anticoagulants; pts = patients. (Source: Stein B, Halperin JL, Fuster V.30) rating 800 patients with chronic atrial fibrillation evaluated quinidine for maintenance of normal sinus rhythm following electrical cardioversion.37 Although quinidine was more effective than a placebo in preventing recurrent atrial fibrillation (50% at one year versus 25% per year in the control groups) the risk of death was threefold greater among drug-treated patients (2.9% versus 0.8% with placebo; odds ratio 2.89, p < 0.05).
The mechanism by which mortality occurs is speculative, but pro-arrhythmic drug toxicity is one possibility.38 The risk of the latter (approximately 5% per year) might seem to outweigh a 3% per year annual risk from quinidine, pointing to the advantage of elimination or prevention of atrial fibrillation. On the other hand, atrial fibrillation may be more important as a marker of thromboembolic risk rather than the primary cause of stroke. Elimination of the dysrhythmia as a means of preventing ischaemic stroke remains an untested hypothesis.
Prospects for embolism prevention
Atrial fibrillation is now recognized as a major risk factor for the development of ischaemic stroke, particularly among elderly patients. But the rhythm disturbance represents a marker of associated cardiovascular pathology which may be more directly at the root of many cases of stroke than cardioembolic mechanisms alone. The effectiveness and relative safety of chronic anticoagulant therapy with warfarin has been validated in three separate clinical trials, supporting a thrombotic mechanism for most of the strokes which occur in patients with atrial fibrillation, and the success of therapy with aspirin in younger individuals in one of the studies suggests that administration of this platelet inhibitor may be sufficient for some patients with nonvalvular atrial fibrillation.
Rheumatic mitral valve disease, prosthetic heart valves and prior thromboembolism identify patients at very high risk of stroke, and advancing age and congestive heart failure related to left ventricle dysfunction also appear to be related to risk, but the dimensions of the left atrium as determined by M-mode or two-dimensional transthoracic echocardiography do not appear to predict ischaemic stroke or systemic thromboembolic events in patients with nonvalvular atrial fibrillation. Left atrial enlargement has been identified as a risk factor for embolism among patients with rheumatic or prosthetic valvular heart disease associated with atrial fibrillation, and more comprehensive analyses of atrial volume, which take into account the extent and pattern of mitral regurgitation, may show such a relationship among others in the future. The exact role of transoesophageal echocardiography for risk stratification and identification of patients requiring therapy with an anticoagulant rather than a platelet inhibitor has not yet been clarified.
A pressing clinical concern is the identification of additional subgroups of patients at such increased risk as to regularly justify maintenance anticoagulant therapy and, conversely, whether there are others at comparatively low risk for whom aspirin alone will prove sufficient. At this juncture, the proportion of ischaemic strokes in patients with atrial fibrillation which have a cardioembolic mechanism has not been defined, and it is possible that warfarin and aspirin exert differential benefit related to stroke mechanism and severity. The significance of associated cerebrovascular disease and its implications for selection of optimum antithrombotic agents are unresolved. The various randomized trials employed slightly different intensities of anticoagulant therapy, leading to speculation that even lower intensities may prove effective with still less risk of bleeding. Indeed, it remains to be established that the low rates of bleeding in patients given anticoagulant medication in these trials will apply in general clinical practice, particularly among older patients treated for longer periods of time.
Goals for the future therefore include collective analysis of data from ongoing and recently completed trials to further stratify patients in terms of the relative risk of stroke based on the aetiology of the dysrhythmia and associated clinical problems. Conclusions from such a large data pool would allow inferences about the optimal therapeutic range for warfarin anticoagulation and selection of some patients for alternative therapy with aspirin. Beyond this lie potentially more effective strategies of antithrombotic therapy.l4 For the moment, however, physicians face the challenge of identifying patients with atrial fibrillation who might benefit from antithrombotic therapy and supervising treatment closely to avoid both the scourges of haemorrhage 37 Coplen SE, Antmann EM, Berlin JA, Hewitt P,
